Back to News
Market Impact: 0.32
Radformation Receives USFDA 510(k) Clearance for OptiPlan Automated VMAT Planning
Source: Business Wire
Healthcare & BiotechTechnology & InnovationRegulation & LegislationProduct Launches
Radformation received FDA 510(k) clearance for OptiPlan, enabling U.S. radiation oncology clinics to adopt its automated volumetric modulated arc therapy (VMAT) treatment-planning technology. The clearance is a meaningful regulatory and commercialization milestone that expands the company’s access to the U.S. oncology-care market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
More News
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- Magnificent 7 loses $1 trillion. The most eye-popping stats from Thursday's tech stock plunge
- Wall Street’s best post-midterm rally in 44 years lasted just one day—then $3 trillion vanished as chip stocks plunged over AI fears
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction